BioSpace News Archive

BridgeBio Pharma, Inc. affiliate QED Therapeutics announced that it will present data at the American Society of Clinical Oncology 2020 Virtual Scientific Program showing clinical advancement for infigratinib, QED’s oral FGFR1-3 inhibitor, in both urothelial carcinoma and cholangiocarcinoma.

The investigational Ebola vaccine regimen leverages Janssen’s established AdVac® and PER.C6® technologies and Bavarian Nordic’s MVA-BN® technology

Data continue to show encouraging clinical activity alongside tolerable safety to deliver a potentially highly differentiated product profile

Median OS of 15.4 months, median PFS of 5.9 months and ORR of 50% observed in recurrent/metastatic HRAS mutant HNSCC

KEAPSAKE is a planned Phase 2 randomized trial exploring telaglenastat with standard of care in first-line treatment of patients with lung cancer with KEAP1/NRF2 mutations

Meridian Bioscience, Inc. announced that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the 40th Annual William Blair Growth Stock Conference on Tuesday, June 9, 2020 at 8:40 AM CT.

Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, announces the presentation of a poster highlighting the clinical trial design of its Phase 2 study of BP1001 at the 2020 American Society of Clinical Oncology Annual Meeting, taking place virtually from May 29-31, 2020.

The on-going dose escalation Phase 1 study has enrolled 44 patients with progressive, metastatic castration-resistant prostate cancer in 11 cohorts.

electroCore, Inc., a commercial-stage bioelectronic medicine company, announced that that a prerecorded virtual presentation featuring Dan Goldberger, Chief Executive Officer, will be available at Little Grapevine™ beginning, May 29, 2020, at 10:30 a.m. Eastern Standard Time.

Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up 36.4% Overall Response Rate (ORR) Maintained SAN CARLOS, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today presented long-term interim data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma during an oral session at the American Society of Clinical Oncology’